Neurocrine Biosciences (NBIX) Non-Current Deferred Tax Liability (2026)
Neurocrine Biosciences' (NBIX) quarterly Non-Current Deferred Tax Liability came in at $91.5 million in Q2 2026.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Non-Current Deferred Tax Liability (2026) Analysis & Trends
Neurocrine Biosciences (NBIX) has reported Non-Current Deferred Tax Liability for 1 consecutive years, with $91.5 million the latest figure, recorded in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |